---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019023"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:17:51.465731+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aytu Q1 FY2024: Adjusted EBITDA $2.2M (+32% YoY), ADHD revenue up 31%

## Summary
- Net revenue $22.1M (down 20% YoY) due to Consumer Health wind-down; Rx segment $17.8M.
- ADHD net revenue $15.1M, up 31% YoY; pediatric revenue $2.6M impacted by payor changes.
- Net loss $8.1M ($1.48/sh) vs $0.7M loss last year; includes $5.9M loss on derivative warrant liabilities.
- Adjusted EBITDA $2.2M vs $1.7M YoY; Rx segment Adjusted EBITDA $2.4M.
- Cash $20.0M at Sept 30, 2023; FDA approvals for manufacturing site transfers for Adzenys and Cotempla.

## SEC filing metadata
- accession: 0001558370-23-019023
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/0001558370-23-019023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/aytu-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019023
- JSON: https://secwatch.observer/filing/0001558370-23-019023.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019023.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported fiscal quarter ended September 30, 2023 results: revenue $22.1 million, net income Net loss during Q1 2024 was $8.1 million, or $1.48 per share, EPS $1.48 per share.
  - Period: fiscal quarter ended September 30, 2023
  - Revenue: $22.1 million
  - Net income: Net loss during Q1 2024 was $8.1 million, or $1.48 per share
  - EPS: $1.48 per share
  - Result: reported results
  source text: operational results for the first quarter of fiscal 2024 ended September 30, 2023. ​ Q1 2024 Commercial Highlights (3 months ending September 30, 2023) · Total net revenue was $22.1 million, compared to $27.7 million. The change is primarily due to the planned wind down of the Company’s Consumer Health segment and the associated decrease in Consumer Health revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837023019023/0001558370-23-019023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.